IMMUNOREACT 5: female patients with rectal cancer have better immune editing mechanisms than male patients - a cohort study.
Gaya SpolveratoMatteo FassanGiulia CapelliMelania ScarpaSilvia NegroValentina ChiminazzoAndromachi KotsaftiImerio AngrimanMichela CampiOttavia De SimoniCesare RuffoloStepanyan AstghikChiara VignottoFederico ScognamiglioGiulia BecherucciGiorgio RivellaFrancesco MarchegianiLuca FacciFrancesca BergamoStefano BrignolaGianluca BusinelloVincenza GuzzardoLuca Dal SantoRoberta SalmasoMarco MassaniAnna PozzaIvana CataldoTommaso SteccaAngelo Paolo Dei TosVittorina ZagonelPierluigi PilatiBoris FranzatoAntonio ScapinelloGiovanni PirozzoloAlfonso RecordareRoberto MerendaGiovanni BordignonSilvio GuerrieroChiara RomitiGiuseppe PortaleChiara CipollariMaurizio ZizzoAndrea PorzionatoMarco AgostiniFrancesco CavallinBarbara Di CamilloRomeo BardiniIsacco MarettoIgnazio CastagliuoloSalvatore PucciarelliMarco ScarpaPublished in: International journal of surgery (London, England) (2023)
Male patients have more frequent oncogene mutations associated with a lower expression of T-cell activation genes. In the healthy mucosa of female patients, more Th1 cells and cytotoxic T cells suggest a potentially better immune response to the tumor. Sex should be considered when defining the treatment strategy for rectal cancer patients or designing prognostic scores.